EA201491617A1 - Соединения для лечения спинальной мышечной атрофии - Google Patents

Соединения для лечения спинальной мышечной атрофии

Info

Publication number
EA201491617A1
EA201491617A1 EA201491617A EA201491617A EA201491617A1 EA 201491617 A1 EA201491617 A1 EA 201491617A1 EA 201491617 A EA201491617 A EA 201491617A EA 201491617 A EA201491617 A EA 201491617A EA 201491617 A1 EA201491617 A1 EA 201491617A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
muscular atrophy
spinal muscular
connections
spinal
Prior art date
Application number
EA201491617A
Other languages
English (en)
Other versions
EA029155B1 (ru
Inventor
Чан-Сун Ли
Соонгиу Чой
Гари Митчелл Карп
Хироо Кояма
Хасан Ратни
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК., Ф. Хоффманн-Ля Рош Аг filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201491617A1 publication Critical patent/EA201491617A1/ru
Publication of EA029155B1 publication Critical patent/EA029155B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Abstract

В настоящей заявке предложены соединения, композиции на их основе и их применение при лечении спинальной мышечной атрофии.
EA201491617A 2012-03-01 2013-02-28 Соединения для лечения спинальной мышечной атрофии EA029155B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605487P 2012-03-01 2012-03-01
PCT/US2013/028131 WO2013130689A1 (en) 2012-03-01 2013-02-28 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
EA201491617A1 true EA201491617A1 (ru) 2015-01-30
EA029155B1 EA029155B1 (ru) 2018-02-28

Family

ID=49083256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491617A EA029155B1 (ru) 2012-03-01 2013-02-28 Соединения для лечения спинальной мышечной атрофии

Country Status (11)

Country Link
US (1) US9371336B2 (ru)
EP (1) EP2819519B1 (ru)
JP (1) JP6092264B2 (ru)
KR (1) KR102099997B1 (ru)
CN (1) CN104302181B (ru)
BR (1) BR112014021531B1 (ru)
CA (1) CA2865957C (ru)
EA (1) EA029155B1 (ru)
HK (1) HK1200056A1 (ru)
MX (1) MX352962B (ru)
WO (1) WO2013130689A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX352861B (es) 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
EA028344B1 (ru) 2012-01-26 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA028382B1 (ru) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
PE20151296A1 (es) * 2012-12-24 2015-10-15 Univ Ramot Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
LT3386511T (lt) 2015-12-10 2021-08-25 Ptc Therapeutics, Inc. Hantingtono ligos gydymo būdai
CA3043755A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc. Methods for modulating rna splicing
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
MX2019014514A (es) 2017-06-05 2020-07-20 Ptc Therapeutics Inc Compuestos para tratar la enfermedad de huntington.
EP3638318A4 (en) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. METHOD OF MODULATION OF RNA SPLICING
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
EA202092001A1 (ru) 2018-03-27 2021-01-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения болезни гентингтона
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
CN111116460A (zh) * 2019-12-31 2020-05-08 阿里生物新材料（常州）有限公司 一种2-氯-4-羟基吡啶-3-甲醛氢溴酸盐的合成方法
CN115836075A (zh) 2020-05-20 2023-03-21 爱尔兰眼力健公司 用于在光学活性装置中使用的氮杂香豆素和氮杂硫代香豆素衍生物
WO2023114539A1 (en) * 2021-12-17 2023-06-22 Pretzel Therapeutics, Inc. Amino chromen-2-one modulators of polrmt

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5599816A (en) 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
AU4231293A (en) 1992-05-13 1993-12-13 E.I. Du Pont De Nemours And Company Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
US6630488B1 (en) 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
ATE551325T1 (de) 2000-01-24 2012-04-15 Astrazeneca Ab Therapeutische morpholino-substituierte verbindungen
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
AU2003237492A1 (en) 2002-06-10 2003-12-22 Acadia Pharmaceuticals Inc. Urotensin ii receptor modulators
AU2003298719A1 (en) 2002-11-25 2004-06-18 Antonia C. Kaloidis Treatment for sma disease
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
DE602004025698D1 (de) 2003-06-20 2010-04-08 Novartis Vaccines & Diagnostic PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
US20050046698A1 (en) 2003-09-02 2005-03-03 Knight Andrew Frederick System and method for producing a selectable view of an object space
EP1687002A4 (en) * 2003-11-10 2008-07-23 Synta Pharmaceuticals Corp CONDENSED HETEROCYCLIC COMPOUNDS
ES2292130T3 (es) 2004-05-04 2008-03-01 Warner-Lambert Company Llc Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos.
WO2006045010A2 (en) 2004-10-20 2006-04-27 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1846397A1 (en) 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2008013997A2 (en) 2006-07-27 2008-01-31 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
AU2008304231A1 (en) 2007-09-27 2009-04-02 Albany Molecular Research, Inc. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019236A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc Methods for treating spinal muscular atrophy
EP2501231B1 (en) 2009-11-20 2016-12-21 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
CN102812023A (zh) 2010-01-13 2012-12-05 韩国巴斯德研究所 抗感染吡啶并(1,2-a)嘧啶类
MX352861B (es) 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
EA028344B1 (ru) 2012-01-26 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA028382B1 (ru) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии

Also Published As

Publication number Publication date
BR112014021531A8 (pt) 2021-06-15
US9371336B2 (en) 2016-06-21
BR112014021531B1 (pt) 2022-10-04
BR112014021531A2 (pt) 2017-06-20
EP2819519A4 (en) 2015-09-02
MX352962B (es) 2017-12-15
JP2015509956A (ja) 2015-04-02
EP2819519A1 (en) 2015-01-07
HK1200056A1 (en) 2015-07-31
US20150166575A1 (en) 2015-06-18
EP2819519B1 (en) 2019-10-23
KR102099997B1 (ko) 2020-04-13
MX2014010406A (es) 2015-03-10
CA2865957A1 (en) 2013-09-06
CN104302181B (zh) 2017-09-15
WO2013130689A1 (en) 2013-09-06
EA029155B1 (ru) 2018-02-28
JP6092264B2 (ja) 2017-03-08
CN104302181A (zh) 2015-01-21
CA2865957C (en) 2020-02-11
KR20140131384A (ko) 2014-11-12

Similar Documents

Publication Publication Date Title
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201890754A1 (ru) Соединения и способы их применения
EA201791007A2 (ru) Соединения и их применения для модуляции гемоглобина
EA201590997A1 (ru) Соединения и способы их применения
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
EA202193044A2 (ru) Способы лечения таупатии
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201201357A1 (ru) Антитела к cd40
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201400579A1 (ru) Антитела к il-36r
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201400178A1 (ru) Лечение рака молочной железы
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
EA201401204A1 (ru) Антитела к il-23p19
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201290642A1 (ru) Соединения и способы
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM